Ji Xiaoyu, Wang Zhiyuan, Sun Wei, Zhang Hao
Department of Thyroid Surgery, The First Hospital of China Medical University, No. 155 Nanjing North Street, Shenyang 110001, China.
Cancers (Basel). 2023 Feb 6;15(4):1033. doi: 10.3390/cancers15041033.
With the development of RNA modification research, N6-methyladenosine (m6A) is regarded as one of the most important internal epigenetic modifications of eukaryotic mRNA. It is also regulated by methylase, demethylase, and protein preferentially recognizing the m6A modification. This dynamic and reversible post-transcriptional RNA alteration has steadily become the focus of cancer research. It can increase tumor stem cell self-renewal and cell proliferation. The m6A-modified genes may be the primary focus for cancer breakthroughs. Although some endocrine cancers are rare, they may have a high mortality rate. As a result, it is critical to recognize the significance of endocrine cancers and identify new therapeutic targets that will aid in improving disease treatment and prognosis. We summarized the latest experimental progress in the m6A modification in endocrine cancers and proposed the m6A alteration as a potential diagnostic marker for endocrine malignancies.
随着RNA修饰研究的发展，N6-甲基腺苷（m6A）被视为真核生物mRNA最重要的内部表观遗传修饰之一。它还受到甲基化酶、去甲基化酶以及优先识别m6A修饰的蛋白质的调控。这种动态可逆的转录后RNA改变已逐渐成为癌症研究的焦点。它可以增加肿瘤干细胞的自我更新和细胞增殖。m6A修饰的基因可能是癌症突破的主要关注点。尽管一些内分泌癌很少见，但它们可能具有较高的死亡率。因此，认识到内分泌癌的重要性并确定有助于改善疾病治疗和预后的新治疗靶点至关重要。我们总结了内分泌癌中m6A修饰的最新实验进展，并提出m6A改变作为内分泌恶性肿瘤的潜在诊断标志物。
